Advanced Solid Cancer
17
7
10
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
11.8%
2 terminated out of 17 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (17)
APG-2449 in Patients With Advanced Solid Tumors
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
ORB-011 In Patients With Advanced Solid Tumors
SIM0613 in Participants With Advanced Solid Tumors
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies